Sadaf Aftab Inamdar, BPharm

CRS:

BJMC

Role:

Pharmacy

Position:

Pharmacist of Record

Email:

sadafafrin786@hotmail.com

Ms. Inamdar is a Pharmacist of Record at BJGMC-CRS, Pune, where she is responsible for study product management, supervision and training for pharmacy staff, establishment and implementation of internal policies and procedures, QA/QC management, inventory control, randomization procedures, study product preparation and dispensing, as well as counseling study participants regarding treatments, adherence monitoring, and product destruction. She is also responsible for preparing the applications for the in-country drug regulatory authority, DCGI. She is knowledgeable about all protocols conducted at BJGMC-CRS, and is well trained in Good Clinical Practices.

She has 14 years of experience in the field of clinical trials at BJGMC-CRS. She worked as Study Pharmacist for a Phase III Clinical Trial ‘Six Weeks Extended Nevirapine’ (SWEN study) in infants to prevent vertical HIV transmission via breastfeeding, conducted collaboration with Johns Hopkins University, Baltimore, USA. She was responsible for managing all the pharmacy related activities. 

She served as an International Committee member on the Adult Clinical Trial Group (ACTG ) Pharmacy Subcommittee from 2009 until January 31, 2014. She also served as Non-voting member on International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Pharmacy Resource Committee, 2010-2013.

She worked as Pharmacist of Record for IMPAACT P1060, P1070, PROMISE study and for ACTG A5207, A5225, A5274, A5273 studies respectively.

Ms. Inamdar is a qualified registered pharmacist with a degree in Pharmacy (BPharm), and she completed a certificate course in Clinical Research and Data Management from Pune University.

  • Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
  • Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S.
  • Lancet. 2008 Jul 26;372(9635):300-13. doi: 10.1016/S0140-6736(08)61114-9.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More